Public Health – Medetomidine and Xylazine Consumer Protection Act
SB 875 creates the "Medetomidine and Xylazine Consumer Protection Act" and adds a new subtitle to the Health-General Article governing retail sales of medetomidine and xylazine products. The bill prohibits retailers from selling or distributing these products unless the purchaser provides proof that the product will be used for an institutional, veterinary, or scientific purpose, and it also bars sales or exposure for sale to anyone under age 21. Retailers that handle these products must keep records of sales, including age verification and documentation of the purchaser’s intended use.
The bill also establishes civil penalties for violations: up to $3,000 for a first violation and up to $6,500 for each subsequent violation. Those penalties must be remitted to the Comptroller and deposited into the Maryland Substance Abuse Fund. The Maryland Department of Health is directed to adopt regulations to implement the subtitle, and the bill takes effect October 1, 2025.
SB 875 would amend the Maryland Health-General Article by creating Subtitle 2F and by expanding the funding sources for the Maryland Substance Abuse Fund to include civil penalties collected under the new law. It would impose new compliance obligations on retailers, including age verification, proof-of-intended-use requirements, and recordkeeping duties, while authorizing the Department of Health to enforce the framework through regulations and civil penalties. The bill affects businesses that sell, prepare, distribute, or advertise medetomidine or xylazine products, including manufacturers, wholesalers, and online platforms doing business in the state.
No committee transcripts or recorded votes were provided, so there is no direct evidence of legislative debate or floor sentiment in the materials supplied. Based on the bill text, the measure appears to be framed as a public health and consumer protection bill aimed at restricting access to substances associated with misuse and diversion, with an emphasis on limiting sales to legitimate institutional, veterinary, or scientific uses.
The main points of potential contention are the breadth of the retailer definition, which includes manufacturers, wholesalers, corporations, partnerships, LLCs, firms, and online platforms, and the practical burden of verifying intended use for each sale. Another likely issue is the age restriction and recordkeeping mandate, which may be viewed by affected businesses as compliance-heavy. Supporters would likely emphasize public health and substance abuse prevention, while opponents may focus on administrative burden, enforcement challenges, and the impact on lawful commercial and scientific supply chains.